Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company explained that its results fluctuate significantly depending on whether milestone revenue is generated under the sales partnership agreement for OBP-301, whether milestone revenue is generated from the achievement of development events, an IPO, M&A or other corporate actions relating to OBP-601, and product sales revenue from OBP-301.
None. There are no matters to be reported in the notes on the going-concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | 503 million yen (YoY +1,662.4%) |
| Operating profit | -767 million yen |
| Ordinary income | -760 million yen |
| Profit attributable to owners of the parent | -762 million yen |
| Net income per share | ¥(26.03) |
| Equity ratio | End of the current fiscal period 72.1% / End of previous period 87.6% |
| Total assets | 4,510 million yen |
| Net assets | 3,257 million yen |
| Cash flows from operating activities | -1,017,309 thousand yen |
| Cash flows from investing activities | 31,525 thousand yen |
| Cash flows from financing activities | 496,622 thousand yen |
| Cash and cash equivalents at end of period | 2,941,682 thousand yen |
| Full-year earnings forecast | Not disclosed (not published because it is difficult to make a reasonable earnings forecast) |
| Annual Dividend Forecast | 0.00 yen → 0.00 yen（0.0） |
| Segment revenue | Not disclosed (omitted because the company has a single segment, the drug discovery business) |
| Segment profit | Not disclosed (omitted because the company has a single segment, the drug discovery business) |
| Depreciation and amortization | 73 thousand yen |
| Disclosure regarding the going concern assumption | None. There are no matters to be reported in the notes on the going-concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Not disclosed (no information on changes in the scope of consolidation because the company is non-consolidated) |
| Material subsequent events | Between 1 July and 31 July 2026, part of the 13th and 14th stock acquisition rights were exercised, resulting in the issuance of 146,000 common shares. The total exercise price was ¥102,752 thousand, and the increases in share capital and capital surplus were ¥52,106 thousand each. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for analysts) |
| Issued Shares at Period-End | 29,319,700 shares |
| Treasury Shares at Period-End | 24,943 shares |
| Factors Behind Changes in Business Performance | The company explained that its results fluctuate significantly depending on whether milestone revenue is generated under the sales partnership agreement for OBP-301, whether milestone revenue is generated from the achievement of development events, an IPO, M&A or other corporate actions relating to OBP-601, and product sales revenue from OBP-301. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that its results fluctuate significantly depending on whether milestone revenue is generated under the sales partnership agreement for OBP-301, whether milestone revenue is generated from development events, an IPO, M&A or other matters relating to OBP-601, and product sales revenue from OBP-301. It did not explicitly state a direct causal relationship with the increase in net sales during the interim period.